BRAF inhibition linked to enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma

Metastatic melanoma patients treated with BRAF-targeted therapy had  increased melanoma antigen expression, T-cell infiltrate, and T-cell cytotoxicity, also decreased immunosuppressive cytokines, which allows for a more favorable tumor microenvironment.